Skip to main content Skip to navigation
Hamburger Menu
Search icon
Mini Cart
Empty CartYou are not signed in.
Country Selector Country Selector
Singapore (English)
Profile Icon Profile Icon
Sign-in/Register UserName
Mini Cart
Empty CartYou are not signed in.
Products

Link Arrow
Solutions

Link Arrow
Discover & Learn

Link Arrow
Resources & Tools

Link Arrow
Support

Link Arrow
Search icon Search icon
Close Menu
    Mini Cart
    Empty CartYou are not signed in.
    Expand menu Expand menu
      Loading...
      Alert Icon
      Purified NA/LE Anti-Human CD20 Obinutuzumab Biosimilar

      BD Pharmingen™ Purified NA/LE Anti-Human CD20 Obinutuzumab Biosimilar

      Clone Obinutuzumab.rMAb (also known as Obinutuzumab Biosimilar) (RUO)

      View all Formats
      570921
      EA (1 Each)
      0.5 mg
      Add Product To QuoteAdd to Quote
      Save to Quote ListRequest Bulk Reagent Quote
      Product Details
      Down Arrow


      BD Pharmingen™
      B1; Bp35; LEU-16; MS4A1
      Human (QC Testing)
      Human IgG1, κ
      Human CD20
      Flow cytometry (Routinely Tested), Cytotoxicity (Tested During Development)
      1.0 mg/ml
      931
      AB_3686112
      No azide/low endotoxin: Aqueous buffered solution containing no preservative, 0.2 µm sterile filtered. Endotoxin level is ≤0.01 EU/µg (≤0.001 ng/µg) of protein as determined by the LAL assay.
      RUO


      Preparation And Storage

      Store undiluted at 4°C. The monoclonal antibody was purified from tissue culture supernatant or ascites by affinity chromatography. This preparation contains no preservatives, thus it should be handled under aseptic conditions.
      Show More blue down arrow Show Less blue up arrow

      Product Notices

      1. For U.S. patents that may apply, see bd.com/patents.
      2. Please refer to http://regdocs.bd.com to access safety data sheets (SDS).
      3. Please refer to www.bdbiosciences.com/us/s/resources for technical protocols.
      4. Since applications vary, each investigator should titrate the reagent to obtain optimal results.
      5. An isotype control should be used at the same concentration as the antibody of interest.
      Show More blue down arrow Show Less blue up arrow

      Data Sheets

      DownloadTechnical Data Sheet (TDS)
      570921 Rev. 1
      Antibody Details
      Down Arrow
      Obinutuzumab.rMAb

      The Obinutuzumab.rMAb (also known as, Obinutuzumab Biosimilar) is a research grade humanized recombinant human IgG1, kappa antibody that specifically recognizes the extracellular domain of human CD20 similarly to the therapeutic Obinutuzumab antibody. The Obinutuzumab.rMAb uses the same variable region sequences as Obinutuzumab, combined with constant region sequences derived from consensus sequences of human IgG1, kappa. Obinutuzumab triggers target cell death through multiple mechanisms including complement-dependent cytotoxicity (CDC), antibody-dependent cellular cytotoxicity (ADCC), and apoptosis. The therapeutic Obinutuzumab has been approved to treat human B cell malignancies, autoimmune disorders, and transplant rejection. CD20 is a 33-37 kDa, unglycosylated four-transmembrane phosphoprotein with a cytoplasmic N-terminus and C-terminus that is encoded by MS4A1 (Membrane-spanning 4-domains, subfamily A, member 1). CD20 is expressed on pre-B-cells, naive and activated B cells, memory B cells, and at lower levels on a small subset of T cells but is absent from plasmablasts and plasma cells. It is also expressed on most malignant B cells and CD20-positive T-cell lymphomas. CD20 functions in mediating calcium transport and B cell activation, differentiation, and survival.

         The Obinutuzumab.rMAb is intended for research use only. It is not intended for use in therapeutic or diagnostic procedures for humans or animals.

      570921 Rev. 1
      Format Details
      Down Arrow
      NA/LE
      NA/LE refers to the culture and purification methods and buffer used to produce purified antibodies with no azide and low endotoxin: Aqueous buffered solution containing no preservative, 0.2µm sterile filtered. Endotoxin level is =0.01 EU/µg (=0.001 ng/µg) of protein as determined by the LAL assay.NA/LE are perfectly suited to be used in culture or in vivo (for nonhuman studies) for functional assays — blocking, neutralizing, activation or depletion — where the presence of azide may damage cells or exogenous endotoxin may signal or activate cells.
      NA/LE
      570921 Rev.1
      Citations & References
      Down Arrow

      Development References (4)

      1. Almasri NM, Duque RE, Iturraspe J, Everett E, Braylan RC. Reduced expression of CD20 antigen as a characteristic marker for chronic lymphocytic leukemia. Am J Hematol. 1992; 40:259-263. (Biology).
      2. Brekke OH, Sandlie I. Therapeutic antibodies for human diseases at the dawn of the twenty-first century.. Nat Rev Drug Discov. 2003; 2(1):52-62. (Biology). View Reference
      3. Hultin LE, Hausner MA, Hultin PM, Giorgi JV. CD20 (pan-B cell) antigen is expressed at a low level on asubpopulation of human T lymphocytes. Cytometry. 1993; 14:196-204. (Biology).
      4. Tobinai K, Klein C, Oya N, Fingerle-Rowson G. A Review of Obinutuzumab (GA101), a Novel Type II Anti-CD20 Monoclonal Antibody, for the Treatment of Patients with B-Cell Malignancies.. Adv Ther. 2017; 34(2):324-356. (Biology). View Reference
      View All (4) View Less
      570921 Rev. 1

      Please refer to Support Documents for Quality Certificates

       

      Global - Refer to manufacturer's instructions for use and related User Manuals and Technical data sheets before using this products as described

       

      Comparisons, where applicable, are made against older BD Technology, manual methods or are general performance claims.  Comparisons are not made against non-BD technologies, unless otherwise noted.

      For Research Use Only. Not for use in diagnostic or therapeutic procedures.